A number of studies have demonstrated an oncogenic role of SHP2 in diverse types of cancer, and the upregulated expression of SHP2 in NSCLC is associated with invasive behaviour and poor prognosis via multiple mechanisms; for example, the growth of KRAS-mutant NSCLC is inhibited by inhibition of SHP2 in vivo [4]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.